Serum IGF- I var normaliseret ved undersøgelsens slutning (uge 12) hos 9, 7%, 38, 5%, 75% og 82% af patienterne be - handlet med hhv. placebo, 10 mg/ dag, 15 mg/ dag eller 20 mg/ dag SOMAVERT.
The serum IGF-1 was normalised at the end of the study (week 12) in 9.7%, 38.5%, 75% and 82% of subjects treated with placebo, 10 mg/ day, 15 mg/ day or 20 mg/ day SOMAVERT respectively.